Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors

ACS Chemical Neuroscience

Volumn 5, Issue 7, 2014, Pages 588-596

  Seo, Young Jun ^a,b   Kang, Yeona ^a   Muench, Lisa ^c   Reid, Alicia ^d   Caesar, Shannon ^a   Jean, Logan ^a   Wagner, Florence ^e   Holson, Edward ^e   Haggarty, Stephen J ^f   Weiss, Philipp ^g   King, Payton ^a   Carter, Pauline ^a   Volkow, Nora D ^c,h   Fowler, Joanna S ^a,i   Hooker, Jacob M ^a,f   Kim, Sung Won ^c,i  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b Chonbuk National University   (South Korea)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d CITY UNIVERSITY OF NEW YORK   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

ⁱ STONY BROOK UNIVERSITY   (United States)

Author keywords

benzamides; blood brain barrier permeability; Histone deacetylase; positron emission tomography

Indexed keywords

BENZAMIDE DERIVATIVE; CARBON 11; ENTINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; TACEDINALINE; TRICHOSTATIN A; VORINOSTAT; CARBON; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; RECOMBINANT PROTEIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; ISOTOPE LABELING; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STEADY STATE; ANIMAL; BRAIN; CAPILLARY PERMEABILITY; CHEMISTRY; DIAGNOSTIC USE; DRUG SCREENING; FEMALE; METABOLISM; PAPIO ANUBIS; PROCEDURES; SCINTISCANNING; SYNTHESIS;

ANIMALS; BENZAMIDES; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CARBON RADIOISOTOPES; DRUG EVALUATION; FEMALE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; PAPIO ANUBIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS;

EID: 84904417032     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500021p     Document Type: Article

References (49)

1. Bernal, A. J. and Jirtle, R. L. (2010) Epigenomic Disruption: The Effects of Early Developmental Exposures Birth Defects Res., Part A 88, 938-944
2. Bierne, H., Hamon, M., and Cossart, P. (2012) Epigenetics and Bacterial Infections Cold Spring Harbor Perspect. Med. 2, x 10.1101/cshperspect.a010272
3. Majumdar, G., Adris, P., Bhargava, N., Chen, H., and Raghow, R. (2012) Pan-Histone Deacetylase Inhibitors Regulate Signaling Pathways Involved in Proliferative and Pro-Inflammatory Mechanisms in H9c2 Cells BMC Genomics 13, 709-728
4. Esteller, M. (2007) Cancer Epigenomics: DNA Methylomes and Histone-Modification Maps Nat. Rev. Genet. 8, 286-298 (Pubitemid 46439286)
5. Tsankova, N., Renthal, W., Kumar, A., and Nestler, E. J. (2007) Epigenetic Regulation in Psychiatric Disorders Nat. Rev. Neurosci. 8, 355-367 (Pubitemid 46652469)
6. Hyman, S. E. (2012) Target Practice: Hdac Inhibitors for Schizophrenia Nat. Neurosci. 15, 1180-1181
7. Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., and Pazdur, R. (2007) FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma Oncologist 12, 1247-1252 (Pubitemid 350106355)
8. Ramaswamy, B., Fiskus, W., Cohen, B., Pellegrino, C., Hershman, D. L., Chuang, E., Luu, T., Somlo, G., Goetz, M., Swaby, R., Shapiro, C. L., Stearns, V., Christos, P., Espinoza-Delgado, I., Bhalla, K., and Sparano, J. A. (2012) Phase I-II Study of Vorinostat Plus Paclitaxel and Bevacizumab in Metastatic Breast Cancer: Evidence for Vorinostat-Induced Tubulin Acetylation and Hsp90 Inhibition in Vivo Breast Cancer Res. Treat. 132, 1063-1072
9. Lee, E. Q., Puduvalli, V. K., Reid, J. M., Kuhn, J. G., Lamborn, K. R., Cloughesy, T. F., Chang, S. M., Drappatz, J., Yung, W. K. A., Gilbert, M. R., Robins, H. I., Lieberman, F. S., Lassman, A. B., McGovern, R. M., Xu, J. H., Desideri, S., Ye, X. B., Ames, M. M., Espinoza-Delgado, I., Prados, M. D., and Wen, P. Y. (2012) Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03 Clin. Cancer Res. 18, 6032-6039
10. Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., and Trepel, J. B. (2013) Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane with or without Entinostat in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment with a Nonsteroidal Aromatase Inhibitor J. Clin. Oncol. 31, 2128-2135
11. Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., and Rumbaugh, G. (2010) Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease Neuropsychopharmacol. 35, 870-880
12. Golden, S. A., Christoffel, D. J., Heshmati, M., Hodes, G. E., Magida, J., Davis, K., Cahill, M. E., Dias, C., Ribeiro, E., Ables, J. L., Kennedy, P. J., Robison, A. J., Gonzalez-Maeso, J., Neve, R. L., Turecki, G., Ghose, S., Tamminga, C. A., and Russo, S. J. (2013) Epigenetic Regulation of Rac1 Induces Synaptic Remodeling in Stress Disorders and Depression Nat. Med. 19, 337-344
13. Abe, T. and Zukin, R. S. (2008) Epigenetic Targets of Hdac Inhibition in Neurodegenerative and Psychiatric Disorders Curr. Opin. Pharmacol. 8, 57-64
14. Kazantsev, A. G. and Thompson, L. M. (2008) Therapeutic Application of Histone Deacetylase Inhibitors for Central Nervous System Disorders Nat. Rev. Drug Discovery 7, 854-868
15. Price, S. and Dyke, H. J. (2007) Histone Deacetylase Inhibitors: An Analysis of Recent Patenting Activity Expert Opin. Ther. Pat. 17, 745-765 (Pubitemid 47249143)
16. Kim, S. W., Hooker, J. M., Otto, N., Win, K., Muench, L., Shea, C., Carter, P., King, P., Reid, A. E., Volkow, N. D., and Fowler, J. S. (2013) Whole-Body Pharmacokinetics of Hdac Inhibitor Drugs, Butyric Acid, Valproic Acid and 4-Phenylbutyric Acid Measured with Carbon-11 Labeled Analogs by Pet Nucl. Med. Biol. 40, 912-918
17. 11C]MS-275 Using Positron Emission Tomography ACS Chem. Neurosci. 1, 65-73
18. Hanson, J. E., La, H., Plise, E., Chen, Y. H., Ding, X., Hanania, T., Sabath, E. V., Alexandrov, V., Brunner, D., Leahy, E., Steiner, P., Liu, L., Scearce-Levie, K., and Zhou, Q. (2013) SAHA Enhances Synaptic Function and Plasticity in Vitro but Has Limited Brain Availability in Vivo and Does Not Impact Cognition PLoS One 8, e69964
19. Schreiber, S. L. (2011) Organic Synthesis toward Small-Molecule Probes and Drugs Proc. Natl. Acad. Sci. U.S.A. 108, 6699-6702
20. Kim, J. Y., Shen, S., Dietz, K., He, Y., Howell, O., Reynolds, R., and Casaccia, P. (2010) HDAC1 Nuclear Export Induced by Pathological Conditions Is Essential for the Onset of Axonal Damage Nat. Neurosci. 13, 180-189
21. Guan, J. S., Haggarty, S. J., Giacometti, E., Dannenberg, J. H., Joseph, N., Gao, J., Nieland, T. J., Zhou, Y., Wang, X., Mazitschek, R., Bradner, J. E., DePinho, R. A., Jaenisch, R., and Tsai, L. H. (2009) HDAC2 Negatively Regulates Memory Formation and Synaptic Plasticity Nature 459, 55-60
22. Graff, J., Rei, D., Guan, J. S., Wang, W. Y., Seo, J., Hennig, K. M., Nieland, T. J., Fass, D. M., Kao, P. F., Kahn, M., Su, S. C., Samiei, A., Joseph, N., Haggarty, S. J., Delalle, I., and Tsai, L. H. (2012) An Epigenetic Blockade of Cognitive Functions in the Neurodegenerating Brain Nature 483, 222-226
23. Kortagere, S., Chekmarev, D., Welsh, W. J., and Ekins, S. (2008) New Predictive Models for Blood-Brain Barrier Permeability of Drug-Like Molecules Pharm. Res. 25, 1836-1845
24. Syvanen, S., Lindhe, O., Palner, M., Kornum, B. R., Rahman, O., Langstrom, B., Knudsen, G. M., and Hammarlund-Udenaes, M. (2009) Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-glycoprotein Transport Drug Metab. Dispos. 37, 635-643
25. Fan, Y., Unwalla, R., Denny, R. A., Di, L., Kerns, E. H., Diller, D. J., and Humblet, C. (2010) Insights for Predicting Blood-Brain Barrier Penetration of Cns Targeted Molecules Using Qspr Approaches J. Chem. Inf. Model. 50, 1123-1133
26. Kattar, S. D., Surdi, L. M., Zabierek, A., Methot, J. L., Middleton, R. E., Hughes, B., Szewczak, A. A., Dahlberg, W. K., Kral, A. M., Ozerova, N., Fleming, J. C., Wang, H., Secrist, P., Harsch, A., Hamill, J. E., Cruz, J. C., Kenific, C. M., Chenard, M., Miller, T. A., Berk, S. C., and Tempest, P. (2009) Parallel Medicinal Chemistry Approaches to Selective HDAC1/HDAC2 Inhibitor (SHI-1:2) Optimization Bioorg. Med. Chem. Lett. 19, 1168-1172
27. 11C Int. J. Radiat. Appl. Instrum. A 28, 49-52
28. 2 Nucl. Med. Biol. 24, 93-97 (Pubitemid 27145600)
29. 11C] methane Appl. Radiat. Isot. 48, 153-157 (Pubitemid 27079506)
30. 11C]Methyl Triflate Int. J. Radiat. Appl. Instrum. A 43, 1383-1385
31. 11C]Melatonin Int. J. Radiat. Appl. Instrum. A 38, 1073-1077 (Pubitemid 18081684)
32. Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., Harsch, A., Heidebrecht, R., Hughes, B., Jung, J., Kenific, C. M., Kral, A. M., Meinke, P. T., Middleton, R. E., Ozerova, N., Sloman, D. L., Stanton, M. G., Szewczak, A. A., Tyagarajan, S., Witter, D. J., Secrist, J. P., and Miller, T. A. (2008) Exploration of the Internal Cavity of Histone Deacetylase (HDAC) with Selective HDAC1/HDAC2 Inhibitors (SHI-1:2) Bioorg. Med. Chem. Lett. 18, 973-978 (Pubitemid 351179353)
33. el-Beltagi, H. M., Martens, A. C., Lelieveld, P., Haroun, E. A., and Hagenbeek, A. (1993) Acetyldinaline: A New Oral Cytostatic Drug with Impressive Differential Activity against Leukemic Cells and Normal Stem Cells - Preclinical Studies in a Relevant Rat Model for Human Acute Myelocytic Leukemia Cancer Res. 53, 3008-3014 (Pubitemid 23210304)
34. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., and Pavletich, N. P. (1999) Structures of a Histone Deacetylase Homologue Bound to the Tsa and Saha Inhibitors Nature 401, 188-193 (Pubitemid 29436325)
35. Wang, D. F., Wiest, O., Helquist, P., Lan-Hargest, H. Y., and Wiech, N. L. (2004) On the Function of the 14 a Long Internal Cavity of Histone Deacetylase-Like Protein: Implications for the Design of Histone Deacetylase Inhibitors J. Med. Chem. 47, 3409-3417 (Pubitemid 38746091)
36. Hendricks, J. A., Keliher, E. J., Marinelli, B., Reiner, T., Weissleder, R., and Mazitschek, R. (2011) In Vivo Pet Imaging of Histone Deacetylases by F-18-Suberoylanilide Hydroxamic Acid (F-18-Saha) J. Med. Chem. 54, 5576-5582
37. Zeglis, B. M., Pillarsetty, N., Divilov, V., Blasberg, R. A., and Lewis, J. S. (2011) The Synthesis and Evaluation of N -1-(4-(2-[F-18]-Fluoroethyl) Phenyl)- N -8-Hydroxyoctanediamide ([F-18]-Fesaha), a Pet Radiotracer Designed for the Delineation of Histone Deacetylase Expression in Cancer Nucl. Med. Biol. 38, 683-696
38. Seo, Y. J., Muench, L., Reid, A., Chen, J., Kang, Y., Hooker, J. M., Volkow, N. D., Fowler, J. S., and Kim, S. W. (2013) Radionuclide Labeling and Evaluation of Candidate Radioligands for Pet Imaging of Histone Deacetylase in the Brain Bioorg. Med. Chem. Lett. 23, 6700-6705
39. 11c]Kb631-a Candidate Radioligand for Histone Deacetylase Isozyme 6 (Hdac6) J. Labelled Compd. Radiopharm. 56, S319
40. Hooker, J. M., Xu, Y., Schiffer, W., Shea, C., Carter, P., and Fowler, J. S. (2008) Pharmacokinetics of the Potent Hallucinogen, Salvinorin a in Primates Parallels the Rapid Onset and Short Duration of Effects in Humans NeuroImage 41, 1044-1050
41. Riva, L., Blaney, S. M., Dauser, R., Nuchtern, J. G., Durfee, J., McGuffey, L., and Berg, S. L. (2000) Pharmacokinetics and Cerebrospinal Fluid Penetration of CI-994 (n-acetyldinaline) in the Nonhuman Primate. Clin. Cancer Res. 6 (3) 994-997 (Pubitemid 30159359)
42. Ertl, P., Rohde, B., and Selzer, P. (2000) Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties J. Med. Chem. 43, 3714-3717
43. Schroeder, A., Lewis, M. C., Fass, D. M., Wagner, F. F., Zhang, Y. L., Hennig, K. M., Gale, J., Zhao, W. N., Reis, S., Barker, D. D., Berry-Scott, E., Kim, S. W., Clore, E. L., Hooker, J. M., Holson, E. B., Haggarty, S. J., and Petryshen, T. L. (2013) A Selective Hdac 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests PLoS One 8, e71323
44. Chou, C. J., Herman, D., and Gottesfeld, J. M. (2008) Pimelic Diphenylamide 106 Is a Slow, Tight-Binding Inhibitor of Class I Histone Deacetylases J. Biol. Chem. 283, 35402-35409
45. Lauffer, B. E., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., Ortwine, D. F., Gunzner, J., Modrusan, Z., Neumann, L., Koth, C. M., Lupardus, P. J., Kaminker, J. S., Heise, C. E., and Steiner, P. (2013) Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability J. Biol. Chem. 288, 26926-26943
46. Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A. M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., Boesche, M., Delling, M., Dumpelfeld, B., Eberhard, D., Huthmacher, C., Mathieson, T., Poeckel, D., Reader, V., Strunk, K., Sweetman, G., Kruse, U., Neubauer, G., Ramsden, N. G., and Drewes, G. (2011) Chemoproteomics Profiling of Hdac Inhibitors Reveals Selective Targeting of Hdac Complexes Nat. Biotechnol. 29, 255-265
47. 3H]CI-994 Autoradiography Epigenetics 8, 756-764
48. Di, L., Rong, H. J., and Feng, B. (2013) Demystifying Brain Penetration in Central Nervous System Drug Discovery J. Med. Chem. 56, 2-12
49. Katragadda, M., Magotti, P., Sfyroera, G., and Lambris, J. D. (2006) Hydrophobic Effect and Hydrogen Bonds Account for the Improved Activity of a Complement Inhibitor, Compstatin J. Med. Chem. 49, 4616-4622 (Pubitemid 44162688)